BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19858401)

  • 1. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.
    Mucci LA; Powolny A; Giovannucci E; Liao Z; Kenfield SA; Shen R; Stampfer MJ; Clinton SK
    J Clin Oncol; 2009 Nov; 27(33):5627-33. PubMed ID: 19858401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.
    Yang M; Zu K; Mucci LA; Rider JR; Fiorentino M; Clinton SK; Loda M; Stampfer MJ; Giovannucci E
    Cancer Causes Control; 2016 Aug; 27(8):1043-7. PubMed ID: 27379990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Connelly RR; Moul JW
    J Urol; 1998 Aug; 160(2):459-65. PubMed ID: 9679898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
    Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
    Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
    Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
    J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting prostatic biopsy Gleason sum under grading.
    Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
    J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
    Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
    Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of microvessel density in prostate cancer core biopsy.
    Dugonjić AS; Usaj SK; Eri Z; Latinović LT
    Vojnosanit Pregl; 2015 Apr; 72(4):317-27. PubMed ID: 26040177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
    Bill-Axelson A; Holmberg L; Filén F; Ruutu M; Garmo H; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Adami HO; Johansson JE;
    J Natl Cancer Inst; 2008 Aug; 100(16):1144-54. PubMed ID: 18695132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study.
    Van Blarigan EL; Gerstenberger JP; Kenfield SA; Giovannucci EL; Stampfer MJ; Jones LW; Clinton SK; Chan JM; Mucci LA
    Cancer Prev Res (Phila); 2015 Oct; 8(10):962-967. PubMed ID: 26276753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.
    Ritch CR; You C; May AT; Herrell SD; Clark PE; Penson DF; Chang SS; Cookson MS; Smith JA; Barocas DA
    Urology; 2014 Jun; 83(6):1309-15. PubMed ID: 24746665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
    J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.